PEP/NEWS — Peptide intel. Daily.

GLP-1 RECEPTOR AGONIST USE LINKED TO LOWER SEPSIS CARDIOMYOPATHY RISK IN REAL-WORLD T2D COHORTSHORT-TERM BIOLOGICAL STRESS CAN SHIFT EPIGENETIC CLOCK READINGS BY YEARSTITIN N2A-MARP COMPLEX LIMITS LONGITUDINAL MUSCLE GROWTH UNDER MECHANICAL STRETCHPLANNED EXERCISE — NOT GENERAL ACTIVITY — ERASES KEY EPIGENETIC AGING MARKERS IN MUSCLETHYMUS SINGLE-CELL MAP REVEALS IMMUNE SELECTION PRESSURE SHIFTS WITH AGESENESCENT SECRETOME FROM CHEMO DRIVES METASTASIS VIA METABOLIC REPROGRAMMING IN NEW NATURE AGING DATAAMPK DECOUPLING FROM FATTY ACID SYNTHESIS PRESERVES LATE-LIFE FITNESS IN YEAST WITHOUT CALORIC RESTRICTIONPLASMA PROTEOMICS CAN FLAG LIVER DISEASE RISK UP TO 16 YEARS BEFORE CLINICAL ONSET GLP-1 RECEPTOR AGONIST USE LINKED TO LOWER SEPSIS CARDIOMYOPATHY RISK IN REAL-WORLD T2D COHORTSHORT-TERM BIOLOGICAL STRESS CAN SHIFT EPIGENETIC CLOCK READINGS BY YEARSTITIN N2A-MARP COMPLEX LIMITS LONGITUDINAL MUSCLE GROWTH UNDER MECHANICAL STRETCHPLANNED EXERCISE — NOT GENERAL ACTIVITY — ERASES KEY EPIGENETIC AGING MARKERS IN MUSCLETHYMUS SINGLE-CELL MAP REVEALS IMMUNE SELECTION PRESSURE SHIFTS WITH AGESENESCENT SECRETOME FROM CHEMO DRIVES METASTASIS VIA METABOLIC REPROGRAMMING IN NEW NATURE AGING DATAAMPK DECOUPLING FROM FATTY ACID SYNTHESIS PRESERVES LATE-LIFE FITNESS IN YEAST WITHOUT CALORIC RESTRICTIONPLASMA PROTEOMICS CAN FLAG LIVER DISEASE RISK UP TO 16 YEARS BEFORE CLINICAL ONSET

Last updated August 2, 2026 — I read this morning's peptide research and picked the items that mattered. Fresh brief tomorrow.

◤ Top story · Fight Aging!
FIGHT AGING! TAKES THE SKEPTIC'S SEAT ON THE PEPTIDE CRAZE — AND THE CASE IS WORTH READING...

*A sober counter-read: what the peptide evidence actually supports, and where hype outruns data.*

Fight Aging!

Featured Briefs

◤ Article · Peptide-anchored

NYC NAD+ INFUSION DEATH: WHAT WENT WRONG AND WHAT IT MEANS FOR THE FIELD...

A woman died following an intravenous NAD+ (a compound studied for cellular energy and longevity) infusion administered outside a clinical setting. Experts say the case highlights real risks when unproven IV protocols are run without proper oversight.

Lifespan.io

More Headlines